Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.

Postmarket

Last Trade
Delayed
$42.98
0.54 (1.27%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$42.44
Day's Change
2.32 (5.78%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
42.69
Day's Low
40.27
Volume
(Below Average)
Volume:
1,042,423

10-day average volume:
1,256,801
1,042,423

New York Times stock pops 10% after ValueAct discloses stake

1:31 pm ET August 11, 2022 (MarketWatch)
Print

Shares of New York Times Co. (NYT) were popping more than 10% in afternoon trading Thursday after ValueAct disclosed a stake in the media company. ValueAct Capital Master Fund and related entities own 11.0 million shares of the New York Times, amounting to a 6.7% stake, according to a filing with the Securities and Exchange Commission. ValueAct said in the filing that it used ValueAct Master Fund's working capital to fund the purchase, the aggregate price of which was about $350 million. Parties at ValueAct "acquired the securities of the Issuer reported herein based on their belief that the securities were undervalued and represented an attractive investment opportunity," per the filing, which also noted that representatives of ValueAct "have had and anticipate having further discussions" with New York Times officers. Shares of New York Times have gained 8.0% over the past three months as the S&P 500 has added 7.6%.

-Emily Bary

	

(END) Dow Jones Newswires

August 11, 2022 13:31 ET (17:31 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.